Accessibility helpSkip to navigationSkip to contentSkip to footer
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign In
  • Home
  • World
    Sections
    • World Home
    • Middle East war
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    Most Read
    • China stops buying liquefied gas from US
    • Trump ratchets up pressure on Fed chair Powell to cut rates
    • Harvard balks at Trump administration’s demand for foreign students’ data
    • Could Trump fire the Federal Reserve chair?
    • Yuval Noah Harari: Trump’s world of rival fortresses
  • US
    Sections
    • US Home
    • US Economy
    • US Companies
    • US Politics & Policy
    Most Read
    • China stops buying liquefied gas from US
    • Trump ratchets up pressure on Fed chair Powell to cut rates
    • Harvard balks at Trump administration’s demand for foreign students’ data
    • Could Trump fire the Federal Reserve chair?
    • Yuval Noah Harari: Trump’s world of rival fortresses
  • Companies
    Sections
    • Companies Home
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
    Most Read
    • China stops buying liquefied gas from US
    • Is there life after banking?
    • Trading in two stocks surged before Trump family appointments announced
    • Astronomers claim strongest evidence yet of extraterrestrial life
    • Nvidia chief Jensen Huang flies to Beijing for talks
  • Tech
    Sections
    • Tech Home
    • Artificial intelligence
    • Semiconductors
    • Cyber Security
    • Social Media
    Most Read
    • Nvidia chief Jensen Huang flies to Beijing for talks
    • Number of UK consumers streaming sports illegally has gone ‘through the roof’, police say
    • OpenAI’s mind-boggling growth masks challenges
    • UK bans EVs from some military bases over Chinese spy fears
    • Google ‘wilfully’ monopolised online advertising market, US judge rules
  • Markets
    Sections
    • Markets Home
    • Alphaville
    • Markets Data
    • Crypto
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Monetary Policy Radar
    • Wealth Management
    • Moral Money
    • ETF Hub
    • Fund Management
    • Trading
    Most Read
    • China stops buying liquefied gas from US
    • Trading in two stocks surged before Trump family appointments announced
    • Is the world losing faith in the almighty US dollar?
    • Few US CEOs bought the dip as tariffs rattled markets
    • BP suffers biggest AGM protest vote in five years
  • Climate
  • Opinion
    Sections
    • Opinion Home
    • Columnists
    • The FT View
    • The Big Read
    • Lex
    • Obituaries
    • Letters
    Most Read
    • Yuval Noah Harari: Trump’s world of rival fortresses
    • Americans, it’s time to move to Europe
    • Tariffs ignore the reality of global tech supply chains
    • OpenAI’s mind-boggling growth masks challenges
    • Donald Trump’s gift to globalisation
  • Lex
  • Work & Careers
    Sections
    • Work & Careers Home
    • Business School Rankings
    • Business Education
    • Europe's Start-Up Hubs
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
    • Working It
    Most Read
    • Few US CEOs bought the dip as tariffs rattled markets
    • Three ideas to energise British tech
    • A food tour of the Jersey Shore with Hailee Catalano, the internet’s favourite cooking teacher
    • Bonuses surge for top traders at EU investment firms after cap is lifted
    • Are your team ‘playing you’?
  • Life & Arts
    Sections
    • Life & Arts Home
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Puzzles
    • Travel
    • FT Globetrotter
    Most Read
    • Is there life after banking?
    • Americans, it’s time to move to Europe
    • Is there such a thing as a British video game?
    • ‘A reliable, old-school Italian’ — Jay Rayner reviews Da Mario, Kensington
    • The World of the Cold War — timely reading in an age of US, Russia and China tensions
  • HTSI
MenuSearch
  • Home
  • World
  • US
  • Companies
  • Tech
  • Markets
  • Climate
  • Opinion
  • Lex
  • Work & Careers
  • Life & Arts
  • HTSI
Financial Times
SubscribeSign In

Eli Lilly & Co

  • Friday, 18 April, 2025
    Eli Lilly’s new obesity pill lowers blood sugar and aids weight loss

    Promising late-stage trial results lift US pharmaceutical group’s shares almost 15%

    Eli Lilly’s logo
  • Friday, 28 March, 2025
    EU regulator declines approval for Eli Lilly’s new Alzheimer’s drug

    European Medicines Agency says risks of potentially fatal side effects from donanemab outweigh benefits

    Eli Lilly’s headquarters in Indianapolis, Indiana, US
  • Wednesday, 26 February, 2025
    Pharmaceuticals sector
    Eli Lilly unveils $27bn US investment as corporate America seeks to woo Trump

    Pharmaceutical industry hopes to ward off growing tariff threat

    Close-up of someone holding an injection pen of Zepbound
  • Thursday, 6 February, 2025
    Eli Lilly expects to beat profit forecasts on obesity drug demand

    Shares rebound after disappointing sales of blockbuster medications last year led to sharp sell-off

    A woman is holding the pen upright
  • Friday, 24 January, 2025
    UnhedgedRobert Armstrong
    What’s wrong with Apple now? Premium content

    Plus GLP-1’s and packaged foods

    Apple chief executive Tim Cook, centre, at Donald Trump’s inauguration
  • Thursday, 23 January, 2025
    Pharmaceuticals sector
    Investors lose their appetite for the obesity trade

    Sector knocked by disappointing sales, an unexpected trial result and questions about the size of the market

    From left: Mournjaro, Zepbound, Wegovy, Ozempic with chart
  • Tuesday, 14 January, 2025
    Eli Lilly shares fall after revenue miss for blockbuster weight-loss drugs

    Sales figures for Mounjaro and Zepbound spook investors in world’s biggest drugmaker

    An injection pen of Zepbound, Eli Lilly’s weight loss drug
  • Saturday, 11 January, 2025
    Eli Lilly in advanced talks to buy US cancer biotech for up to $2.5bn

    Scorpion’s drug candidate inhibits a mutation that is a major driver of breast, gynaecological and head and neck cancers

    Eli Lilly logo
  • Friday, 20 December, 2024
    Eli Lilly given US approval to treat sleep disorder with weight-loss drug

    Regulatory go-ahead marks latest boost for drugmaker’s blockbuster anti-obesity franchise

    An Eli Lilly Zepbound injection pen
  • Thursday, 12 December, 2024
    The Big Read
    Could weight-loss drugs treat other chronic diseases?

    Initial research has focused on obesity, but Ozempic, Wegovy and Mounjaro may potentially be used for addiction, heart disease and Alzheimer’s

    A montage of the human organs overlaid with Novo Nordisk and Eli Lilly logos
  • Tuesday, 26 November, 2024
    Healthcare
    Biden proposes wide expansion of US weight-loss drug coverage

    State-backed insurance programmes would fund drugs for obese patients without separate health conditions

    Boxes of Ozempic and Wegovy made by Novo Nordisk on display at a pharmacy in London
  • Wednesday, 30 October, 2024
    Lex
    Eli Lilly’s slip does not mean the weight loss drug craze is over Premium content

    The misses are largely down to inventory issues, rather than weaker demand

    An Eli Lilly & Co. Zepbound injection pen
  • Wednesday, 30 October, 2024
    Shares in weight-loss drugmaker Eli Lilly fall on disappointing sales

    US group revises down upper end of full-year revenue estimates

    Injection pen of Zepbound being held
  • Friday, 11 October, 2024
    UnhedgedRobert Armstrong
    Disinflation takes time Premium content

    And valuing the weight-loss drug manufacturers

    A montage of a trader on the floor of the New York Stock Exchange with an American flag in the background
  • Thursday, 10 October, 2024
    UnhedgedRobert Armstrong
    Is there an obesity drug bubble? Premium content

    A big market narrative with an eerie absence of sceptics

    Injection pens of Novo Nordisk’s weight-loss drug Wegovy
  • Tuesday, 8 October, 2024
    Healthcare costs
    Obesity drugs could cost US health insurance system $35bn, study finds

    CBO analysis says savings from other health benefits would not offset expense of weight-loss jabs

    Boxes of Ozempic and Wegovy
  • Wednesday, 2 October, 2024
    The Big Read
    Can Eli Lilly become the first $1tn drugmaker?

    The company is thriving as weight-loss drugs boom, but investors see warning signs it has reached ‘peak enthusiasm’

    Montage image of David Ricks, chief executive of Eli Lilly, Zepbound medication and a building with the company’s logo on it
  • Tuesday, 1 October, 2024
    Eli Lilly considers testing weight-loss drugs on people who are not overweight

    Drugmaker’s CEO sees chance to widen use of anti-obesity medications for ‘health maintenance’

    Zepbound  medication
  • Wednesday, 4 September, 2024
    News in-depthPharmaceuticals sector
    Investor doubts about Wegovy copycats weigh on health startups

    US telehealth groups including Hims & Hers and Ro could find new revenue streams under threat

    Eden & Sesame, Henry Meds, Ro and Hers weight loss medication
  • Tuesday, 27 August, 2024
    Eli Lilly launches cheaper vial version of blockbuster weight-loss drug

    US group races to overcome production bottleneck to meet demand for anti-obesity medicine Zepbound

    Injection pen of Zepbound
  • Tuesday, 27 August, 2024
    The cost of cracking cancer
    The cost of cracking cancer: what the $1tn race for a cure leaves behind

    The first in an FT series looking at the new energy behind the fight for cancer cures

    A montage showing a scientist wearing protective gear, including a hairnet, mask, and gloves, handling a syringe. To the right, a petri dish with nematodes visible inside. The background features an image of pancreatic cancer cells.
  • Thursday, 15 August, 2024
    Drugs research
    How Roche passed on a potential $14bn-a-year weight-loss pill

    The Swiss company had the first option on a drug that could now become a leading anti-obesity treatment

    Injection pen parts on the Wegovy production line
  • Thursday, 8 August, 2024
    Eli Lilly raises outlook on bumper sales of diabetes and weight loss drugs

    Shares soar as ‘strong performance’ of Mounjaro and Zepbound medicines underpin jump in revenue

    An Eli Lilly sign on its offices in San Diego
  • Wednesday, 7 August, 2024
    Drugs research
    Eli Lilly enters nuclear isotope business to back cancer treatment

    Pharma companies are moving up the supply chain to secure radioactive materials for a new form of drugs

    Eli Lilly plant in New Jersey
  • Monday, 29 July, 2024
    Roche Holding AG
    Roche to fast-track weight-loss pill to compete with rivals

    Swiss drugmaker unveils promising data for obesity drug

    Passers-by are silhouetted as they walk along the banks of river Rhine next to the Roche towers
Previous page You are on page 1 Next page

Useful links

Support

View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareersSuppliers

Legal & Privacy

Terms & ConditionsPrivacy PolicyCookie PolicyManage CookiesCopyrightSlavery Statement & Policies

Services

Share News Tips SecurelyIndividual SubscriptionsProfessional SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on XFT ChannelsFT Schools

Tools

PortfolioFT AppFT Digital EditionFT EditAlerts HubBusiness School RankingsSubscription ManagerNews feedNewslettersCurrency Converter

Community & Events

FT Live EventsFT ForumsFT Leaders Academy

More from the FT Group

Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2025. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
Edition:International
UK
Subscribe for full access

Top sections

  • Home
  • World
    • Middle East war
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
  • US
    • US Economy
    • US Companies
    • US Politics & Policy
  • Companies
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
  • Tech
    • Artificial intelligence
    • Semiconductors
    • Cyber Security
    • Social Media
  • Markets
    • Alphaville
    • Markets Data
    • Crypto
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Monetary Policy Radar
    • Wealth Management
    • Moral Money
    • ETF Hub
    • Fund Management
    • Trading
  • Climate
  • Opinion
    • Columnists
    • The FT View
    • The Big Read
    • Lex
    • Obituaries
    • Letters
  • Lex
  • Work & Careers
    • Business School Rankings
    • Business Education
    • Europe's Start-Up Hubs
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
    • Working It
  • Life & Arts
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Puzzles
    • Travel
    • FT Globetrotter
  • Personal Finance
    • Property & Mortgages
    • Investments
    • Pensions
    • Tax
    • Banking & Savings
    • Advice & Comment
  • HTSI
  • Special Reports

FT recommends

  • Alphaville
  • FT Edit
  • Lunch with the FT
  • FT Globetrotter
  • #techAsia
  • Moral Money
  • Visual and data journalism
  • Newsletters
  • Video
  • Podcasts
  • News feed
  • FT Schools
  • FT Live Events
  • FT Forums
  • FT Leaders Academy
  • myFT
  • Portfolio
  • FT Digital Edition
  • Crossword
  • Our Apps
  • Help Centre
  • Subscribe
  • Sign In